Immunotech Laboratories, Inc. (IMMB) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerImmunotech Laboratories, Inc. (IMMB) trades at $0.0002. Immunotech Laboratories, Inc. focuses on developing and commercializing proprietary proteins for treating immuno-related disorders. The company's flagship compound, ITV-1, targets HIV/AIDS and Hepatitis C. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for IMMB: IMMB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Immunotech Laboratories, Inc. (IMMB) Healthcare & Pipeline Overview
Immunotech Laboratories, Inc. is a pharmaceutical company specializing in the development of proprietary proteins, notably ITV-1, for treating HIV/AIDS, Hepatitis C, and other immuno-related disorders. Operating as a subsidiary of Eco-Petroleum Solutions, Inc., the company focuses on modulating the immune system through its unique therapeutic vaccine.
What Is the Investment Thesis for IMMB?
Immunotech Laboratories, Inc. presents a highly speculative investment opportunity due to its focus on ITV-1, a proprietary protein aimed at treating HIV/AIDS and Hepatitis C. The company's potential hinges on the successful development and commercialization of ITV-1, which could address significant unmet needs in the treatment of these diseases. However, as a subsidiary of Eco-Petroleum Solutions, Inc., its financial performance and strategic direction are closely tied to its parent company. The company's small size and limited resources pose challenges to its ability to navigate the complex regulatory landscape and compete with larger pharmaceutical companies. With a negative P/E ratio of -0.23 and a beta of -77.02, the stock demonstrates high volatility and speculative interest. Investors should carefully consider the risks associated with investing in a small, OTC-traded pharmaceutical company with a limited product pipeline.
Based on FMP financials and quantitative analysis
IMMB Key Highlights
Immunotech Laboratories, Inc. operates as a subsidiary of Eco-Petroleum Solutions, Inc. since June 14, 2017.
- The company's primary product is ITV-1, an immune therapeutic vaccine targeting HIV/AIDS and Hepatitis C.
- The company has a negative Price/Earnings ratio of -0.23, indicating it is not currently profitable.
- The company has a beta of -77.02, suggesting an inverse correlation to market movements and high volatility.
- Immunotech Laboratories, Inc. does not offer a dividend, reflecting its focus on reinvesting earnings into research and development.
Who Are IMMB's Competitors?
IMMB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 78 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 82 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMMB's Key Strengths?
Proprietary protein technology (ITV-1).
- Focus on a specific niche within the pharmaceutical industry (immuno-related disorders).
- Potential for patent protection on ITV-1.
- Operates as a subsidiary of Eco-Petroleum Solutions, Inc.
What Are IMMB's Weaknesses?
Small size and limited resources.
- Dependence on a single product (ITV-1).
- Limited market presence.
- OTC market listing.
What Are the Key Risks for IMMB?
Financial-distress signal — its Altman Z-Score of -1.14 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-9.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays for ITV-1.
- Competition from larger pharmaceutical companies with greater resources.
- Regulatory hurdles and delays in obtaining approvals for ITV-1.
- Limited financial resources and dependence on external funding.
- OTC market listing and associated liquidity risks.
What Threats Does IMMB Face?
- Competition from larger pharmaceutical companies.
- Regulatory hurdles and clinical trial risks.
- Patent expiration and generic competition.
- Changes in healthcare policies and reimbursement rates.
What Are IMMB's Competitive Advantages?
- Proprietary protein technology (ITV-1).
- Focus on a specific niche within the pharmaceutical industry (immuno-related disorders).
- Potential for patent protection on ITV-1.
What Does IMMB Do?
Immunotech Laboratories, Inc. was founded to develop and commercialize proprietary proteins aimed at treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. The company's primary focus is on its flagship compound, ITV-1 (immune therapeutic vaccine), which is a suspension of irreversible pepsin fraction designed to treat HIV/AIDS and Hepatitis C, as well as to modulate the immune system. ITV-1 represents the core of Immunotech's efforts to provide innovative solutions in the field of immune-related therapies. Headquartered in Monrovia, California, Immunotech operates as a subsidiary of Eco-Petroleum Solutions, Inc., since June 14, 2017. This acquisition has allowed Immunotech to continue its research and development activities under the umbrella of a larger entity. The company's strategy revolves around leveraging its proprietary protein technology to address significant unmet needs in the treatment of viral and immune-related diseases. Immunotech's small team is focused on advancing ITV-1 through various stages of development and exploring its potential applications in other immuno-related conditions. The company aims to establish itself as a key player in the development of novel immunomodulatory therapies.
What Products and Services Does IMMB Offer?
- Develop proprietary proteins for treating immuno-related disorders.
- Focus on the development of ITV-1 (immune therapeutic vaccine).
- Target HIV/AIDS and Hepatitis C with ITV-1.
- Modulate the immune system through their therapeutic vaccine.
- Conduct research and development activities to advance ITV-1.
- Operate as a subsidiary of Eco-Petroleum Solutions, Inc.
How Does IMMB Make Money?
- Develop and commercialize proprietary proteins.
- Generate revenue through the sale of ITV-1.
- Focus on treating HIV/AIDS and Hepatitis C.
- Operate as a subsidiary of Eco-Petroleum Solutions, Inc.
What Industry Does IMMB Operate In?
Immunotech Laboratories, Inc. operates within the medical pharmaceutical industry, which is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market for HIV/AIDS and Hepatitis C treatments is well-established but continues to evolve with the development of new therapies. Immunotech's focus on proprietary proteins and immune modulation places it in a niche segment of the market, competing with larger pharmaceutical companies that have broader product portfolios and greater resources. The company's success depends on its ability to differentiate ITV-1 and demonstrate its clinical efficacy and safety.
Who Are IMMB's Key Customers?
- Patients with HIV/AIDS.
- Patients with Hepatitis C.
- Healthcare providers treating immuno-related disorders.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Immunotech Laboratories, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.14 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Immunotech Laboratories, Inc. stands at -9.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -27.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Immunotech Laboratories, Inc. operates in the Healthcare sector. It is headquartered in Monrovia, US. IMMB has traded publicly since 2001.
IMMB Financials
IMMB Latest News
No recent news available for IMMB.
IMMB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IMMB.
Price Targets
Wall Street price target analysis for IMMB.
IMMB MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for IMMB; grades run from A+ (80-100) to F (below 30).
Leadership: Harry H. Zhabilov Jr. McS
CEO
Harry H. Zhabilov Jr. McS serves as the CEO of Immunotech Laboratories, Inc. His background includes experience in managing small teams and overseeing the development of pharmaceutical products. He has a McS degree. His leadership is focused on advancing the company's flagship compound, ITV-1, through the necessary regulatory and clinical milestones. Zhabilov's expertise is crucial in navigating the complex landscape of the pharmaceutical industry and driving the company's strategic initiatives.
Track Record: Under Harry H. Zhabilov Jr.'s leadership, Immunotech Laboratories, Inc. has continued to focus on the development of ITV-1. His tenure has involved navigating the challenges of a small pharmaceutical company operating in a competitive market. Key decisions have included prioritizing research and development efforts and seeking strategic partnerships to support the company's growth. He manages a team of 4 employees.
IMMB OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Immunotech Laboratories, Inc. may not meet the minimum financial standards or reporting requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may be subject to limited regulatory oversight and may not provide as much information to investors as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility.
- OTC Tier: OTC Other
- Limited liquidity due to OTC trading.
- Lack of regulatory oversight compared to major exchanges.
- Potential for higher price volatility.
- Uncertainty regarding financial reporting and disclosure.
- Dependence on a single product (ITV-1).
- Verify the company's financial statements and disclosures.
- Assess the company's management team and their experience.
- Evaluate the potential market for ITV-1.
- Understand the regulatory landscape and clinical trial risks.
- Review the company's patent protection and intellectual property.
- Monitor the company's news and press releases for updates.
- Consult with a financial advisor before investing.
- Focus on developing treatments for HIV/AIDS and Hepatitis C.
- Existence of a proprietary protein technology (ITV-1).
- Operation as a subsidiary of Eco-Petroleum Solutions, Inc.
- CEO with experience in managing pharmaceutical products.
Immunotech Laboratories, Inc. Healthcare Stock: Key Questions Answered
What do analysts say about IMMB stock?
As a thinly traded OTC stock with limited analyst coverage, there is no readily available consensus view on IMMB. The company's valuation is difficult to assess due to its lack of profitability and limited financial disclosures.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on limited publicly available data.
- OTC market stocks carry higher risk than exchange-listed stocks.
- Financial data may not be fully up-to-date.